Applied DNA Sciences Forum: Community User: Moma

Aber es heißt keine Kapitalerhöhung vor 75mio kapitalwert. Heißt ja nur dass die bis dahin sicher keine machen, nicht dass ab dann direkt eine kommt

ja Blender, das habe ich ähnlich gelesen...

DerBlender ernsthaft jetzt?

An unsere Taat-Freunde: Zum Vergleich - taat verkauft gerade ein paar Kippen in Ohio, hat bisher kaum Umsätze, ist aber schon bei einer MK von 140 Mio Euro, also doppelt so hoch bewertet wie DNA.... Und DNA soll "nur" schnellstmöglich ein Helfer gegen eine Pandemie in der laufenden Pandemie sein....

Der Übersetzer ist gut. Da steht was von ohne weitere Nachricht, also wann der Vorgang genau beendet ist bekommen wir wohl gar nicht mit. Im Grunde ist das ja auch keine Frage, wenn das Geschäft rechtsgültig ist. Keine weitere Kapitalerhöhung vor Errreichen eines Kapitalwertes von 75 Mio Dollar, der ist allerdings ja knapp über 10 Dollar pro Aktie erreicht.

mir läuft das alles zu gut....

Lets go

also da ist grundsätzlich viel bereits Bekanntes drin. Auf jeden Fall wollen sie Partnerschaften eingehen, um schnell Ihr Produkt zu erweitern. Genau, was wir eigentlich erwartet haben und auch lesen wollen :)

Wer kann gut english bitte unersetzten

https://www.deepl.com/translator zig mal besser als der google translator

We also seek to develop, acquire, and commercialize, ourselves or with partners, a diverse portfolio of nucleic acid-based therapeutics based on PCR-produced linear DNA to improve existing nucleic acid-based therapeutics or to create new nucleic acid-based therapeutics that address unmet medical needs. We are currently directly engaged in preclinical drug candidate development activities focusing on therapeutically-relevant DNA constructs manufactured via our LinearDNATM platform in the fields of DNA-based anti-viral and anti-cancer vaccines, CAR-T cell immunotherapy and the manufacture of rAAV vectors for gene therapy

Ist es durch das Angebot?

oh Gott, da sind ja Massig Seiten an infos dran :D :D Our proprietary PCR-based DNA LinearDNATM manufacturing platform produces large quantities of DNA for use in nucleic acid-based in vitro medical diagnostics and preclinical nucleic acid-based drug development and manufacturing markets (“Biotherapeutic Contract Research and Manufacturing”) and for supply chain security, anti-counterfeiting and anti-theft technology purposes (“Non-Biologic Tagging”). In response to the SARS-CoV-2 (“COVID-19”) pandemic, the Company developed a PCR-based molecular diagnostic test for COVID-19, which was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (“FDA”) in May 2020. The Company currently manufactures and sells its EUA authorized COVID-19 molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark (“COVID-19 Diagnostic Testing”). In addition, and in further response to the COVID-19 pandemic, the Company developed and is currently offering non-diagnostic COVID-19 pooled surveillance testing to detect instances of COVID-19 in defined populations. The Company’s COVID-19 pooled surveillance testing services are currently offered under the safeCircleTM trademark (“COVID-19 Surveillance Testing”). The Company is also developing an invasive circulating tumor cell capture and identification technology (“iCTC Technology”) which uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes that can be identified and expanded for further analysis. Applied DNA’s LinearDNATM PCR platform is capable of producing large scale DNA, which we believe offers many benefits over the limitations of other large scale DNA manufacturing systems, including: · Speed – Production of DNA via the LinearDNATM platform can be measured in terms of hours, not days and weeks like other large scale DNA manufacturing platforms. · Scale – The LinearDNATM platform is flexible and can be adapted to encompass large quantity production. · Purity – DNA produced via PCR is pure, resulting in only large quantities of the target DNA sequence. Unwanted DNA sequences such as bacterially-derived DNA are not present. · Customization – DNA produced via PCR can be easily chemically modified to suit specific customer applications.

https://fintel.io/doc/sec-applied-dna-sciences-inc-424b5-2021-january-13-18640-714 (bitte aber nochmal durchlesen, mein Börsenenglisch ist teils überschaubar, bzw. ich kenne nicht die US - amerikanischen Gepflogenheiten in Sachen Offering).

heute gehts los, liebe Freunde. Fasten your Seatbelts!

https://fintel.io/doc/sec-applied-dna-sciences-inc-424b5-2021-january-13-18640-714